Sunshine Financial Statements From 2010 to 2026

Stocks USA . 
Stock . Sunshine Biopharma Warrant
SBFMW Stock  USD 0.17  0.07  29.17%   
Sunshine Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sunshine Biopharma's valuation are provided below:
Gross Profit
12.3 M
Profit Margin
(0.16)
Revenue
37.3 M
Earnings Share
(2.21)
Quarterly Revenue Growth
0.116
There are over one hundred nineteen available fundamental trend indicators for Sunshine Biopharma Warrant, which can be analyzed over time and compared to other ratios. All traders should should double-check Sunshine Biopharma's current fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable.

Sunshine Biopharma Total Revenue

42.11 Million

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 9.6 K, Other Operating Expenses of 49.1 M or Total Operating Expenses of 19.9 M, as well as many indicators such as Price To Sales Ratio of 0.066, Dividend Yield of 0.0 or PTB Ratio of 0.0979. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Sunshine Stock
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Sunshine Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.9 M35.1 M9.7 M
Slightly volatile
Total Current Liabilities7.6 M7.3 M2.3 M
Slightly volatile
Accounts Payable6.7 M6.4 M1.4 M
Slightly volatile
Cash11.7 M11.1 M4.4 M
Slightly volatile
Cash And Short Term Investments11.7 M11.1 M4.4 M
Slightly volatile
Common Stock Shares Outstanding847.4 K807 K144.3 K
Slightly volatile
Liabilities And Stockholders Equity36.9 M35.1 M9.7 M
Slightly volatile
Non Current Liabilities Total517.6 K856.4 K576.2 K
Slightly volatile
Other Stockholder Equity112.7 M107.4 M36 M
Slightly volatile
Total Liabilities8.5 M8.1 M2.8 M
Slightly volatile
Total Current Assets31.4 M29.9 M8.4 M
Slightly volatile
Common Stock2.8 K3 K136.1 K
Pretty Stable
Short and Long Term Debt Total780.2 K1.1 M738 K
Slightly volatile
Other Current Liabilities498.2 K340.2 K450.9 K
Slightly volatile
Other Assets97 K92.3 K77.3 K
Slightly volatile
Other Current Assets1.4 M1.3 M323.6 K
Slightly volatile
Short Term Debt227 K238.9 K464.3 K
Pretty Stable
Property Plant And Equipment Net1.8 M1.7 M444.9 K
Slightly volatile
Non Current Assets Total5.5 M5.3 M1.5 M
Slightly volatile
Net Receivables4.7 M4.4 M1 M
Slightly volatile
Intangible Assets3.6 M3.5 M1.2 M
Slightly volatile
Property Plant Equipment6 K6.4 K36.3 K
Slightly volatile
Current Deferred Revenue192.1 K344.8 K163.5 K
Slightly volatile
Long Term Debt1.2 M2.2 M908.4 K
Slightly volatile
Good Will532.6 K599.1 K653.9 K
Slightly volatile
Short and Long Term Debt4.4 M4.2 M1.8 M
Slightly volatile
Capital Stock13.3 K14 K114.7 K
Slightly volatile
Short Term Investments6.1 K6.8 K7.5 K
Slightly volatile
Property Plant And Equipment Gross2.2 M2.1 M547.1 K
Slightly volatile

Sunshine Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense9.6 K10.1 K128.3 K
Slightly volatile
Other Operating Expenses49.1 M46.8 M11.3 M
Slightly volatile
Total Operating Expenses19.9 M19 M5.4 M
Slightly volatile
Selling General Administrative16.9 M16.1 M4.5 M
Slightly volatile
Selling And Marketing Expenses1.1 M1.1 M567.4 K
Slightly volatile
Research Development1.1 M1.1 M433.6 K
Slightly volatile
Depreciation And Amortization303.9 K201.2 K402.9 K
Slightly volatile
Cost Of Revenue29.2 M27.8 M6 M
Slightly volatile
Total Revenue42.1 M40.1 M8.7 M
Slightly volatile
Reconciled Depreciation269.9 K257.1 K81.5 K
Slightly volatile

Sunshine Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities11.2 M10.7 M4.9 M
Slightly volatile
End Period Cash Flow11.7 M11.1 M4.4 M
Slightly volatile
Begin Period Cash Flow19.7 M18.7 M4.7 M
Slightly volatile
Depreciation269.9 K257.1 K65.2 K
Slightly volatile
Change To Netincome12.9 M12.3 M4.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.0660.0694164.4 K
Slightly volatile
Days Sales Outstanding44.2346.56257
Slightly volatile
Average Payables3.8 M3.7 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue4.394.6226.586
Slightly volatile
Capex To Depreciation21.4611.9456.1546
Slightly volatile
Payables Turnover4.775.0278.0369
Slightly volatile
Sales General And Administrative To Revenue0.440.46162
Slightly volatile
Research And Ddevelopement To Revenue0.02930.03082.0802
Slightly volatile
Capex To Revenue0.07270.0765129
Slightly volatile
Cash Per Share11.812.421.7 K
Very volatile
Days Payables Outstanding71.4775.23374
Pretty Stable
Income Quality2.312.20.7638
Slightly volatile
Intangibles To Total Assets0.110.09880.4529
Slightly volatile
Current Ratio6.644.735.5156
Pretty Stable
Receivables Turnover9.8510.3718.0752
Pretty Stable
Capex Per Share3.613.8230
Slightly volatile
Average Receivables2.1 M2 M844.3 K
Slightly volatile
Revenue Per Share42.4944.73180
Slightly volatile
Debt To Assets0.03410.03581.6183
Slightly volatile
Days Of Payables Outstanding71.4775.23374
Pretty Stable
Ebt Per Ebit1.630.831.819
Pretty Stable
Quick Ratio2.542.674.8898
Pretty Stable
Net Income Per E B T1.231.11.0876
Pretty Stable
Cash Ratio1.681.763.866
Pretty Stable
Days Of Sales Outstanding44.2346.56257
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.361.3148
Slightly volatile
Fixed Asset Turnover22.2421.188.1482
Slightly volatile
Debt Ratio0.03410.03581.6183
Slightly volatile
Price Sales Ratio0.0660.0694164.4 K
Slightly volatile
Asset Turnover1.081.030.3442
Slightly volatile

Sunshine Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap339.9 K382.4 K417.4 K
Slightly volatile
Enterprise Value483.5 K544 K593.7 K
Slightly volatile

Sunshine Fundamental Market Drivers

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue344.8 K192.1 K
Cost Of Revenue27.8 M29.2 M
Total Revenue40.1 M42.1 M
Stock Based Compensation To Revenue 4.62  4.39 
Sales General And Administrative To Revenue 0.46  0.44 
Research And Ddevelopement To Revenue 0.03  0.03 
Capex To Revenue 0.08  0.07 
Revenue Per Share 44.73  42.49 
Ebit Per Revenue(0.15)(0.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY